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Mannheim, GermanyObjective. Implementation of outpatient treatment (OT) of deep-vein thrombosis (DVT) is slow despite clear evidence that
it is effective, safe and cost-efficient.
Design and method. An initiative was launched with the help of the Professional Association of Phlebologists of Germany
and the industry to familiarize physicians in private practice who had no prior experience with OTof DVT. Data on quality
of treatment with the low-molecular-weight heparin tinzaparin and phenprocoumon, compliance, clinical outcome, venous
ultrasound, patients’ satisfaction and quality of life were collected in a registry, which was open from July 1999 to December
2000. The results were published and their impact on further management of patients was assessed in second survey reported
here. Patients of both series were followed-up clinically and with ultrasound over the 1st month of treatment.
Results. Of 67 physicians entering 827 patients into the registry 26 answered a questionnaire on how they treated further
patients. Their case load had increased by 450% and data were provided on 540 consecutive patients managed between
January and June 2002. OT increased overall from 76 to 92%, that of popliteo-femoral DVT from 71 to 92%, and that of
pelvic DVT from 38 to 65%. Medical reasons to decide against OT decreased from 89 to 56% (p!.01). Immediate leg
compression was changed from bandaging to medical compression stockings in 20 of the 26 centres (p!.05). In total, data
were gathered from OTof 1124 patients. No secondary hospitalisations were required and only one patient had a documented
progression of the DVT.
Conclusions. OT was successfully implemented in private practices through the initiative of individual physicians with
support of the professional association and sponsoring by the industry—to the benefit of the providers but as much of the
patients and their cost bearers.Keywords: Deep-vein thrombosis; Outpatient treatment; Implementation; Sponsoring.Introduction
A large body of evidence has accumulated demon-
strating that outpatient treatment of acute deep
venous thrombosis (DVT) with low-molecular-weight
heparin (LMWH) is efficient, safe and cost-effective.1–
25 In some specialized centres patients are admitted to
the ward for 1 or 2 days only, in others they are not
admitted but visited at home by nurses, and in again
others they are treated on an outpatient basis. Criteria
for patient selection have been described26 but no
requirement for close follow-up has been reported
largely because major problems have not been
encountered with this strategy. Neither with the
thrombotic event itself or the method of treatment
gave rise to complications in more than a smalling author. Dr Werner Bla¨ttler, MD, Angio Bellaria,
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outpatient management of deep vein thrombosis is
carried out on a very limited scale. A nation-wide
survey in Spain showed that 90% of patients are still
admitted to the hospital, despite the use of LMWH in
88%, and 66% were advised that absolute bed rest was
required.27 According to a recent survey performed in
the USA only 55.6% of patients referred to a teaching
or community hospital are given LMWH and the
hospital stay averaged 7.7 days.28
In our private clinics for vascular diseases we have
performed outpatient treatment of DVT routinely
since 1979.2,3 We intended to help other vascular
physicians to implement a straightforward treatment
strategy and set up a prospective registry under the
name controlled outpatient management of DVT
(COM I). Data were reported from 67 participating
practices where 76.3% of 827 patients were treated as
outpatients between July 1999 and December 2000.29
During a follow-up period of 1 month no evidence ofEur J Vasc Endovasc Surg 30, 319–324 (2005)
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hospitalisation was recorded. Anticoagulant treatment
was used routinely combined in all patents with leg
compression and deliberate ambulation. Relief of
symptoms, restoration of quality of life and resump-
tion of daily working capability were prompt.
In July 2002, we assessed the impact of the initiative
by a second survey termed COM II. Here, we report
how the physicians changed their approach toward
patients with DVT.† A list of the participating practices is provided in the Appendix A.Methods
In an effort broadly to introduce outpatient treatment
of DVT in Germany we launched an initiative with
physicians in private practice who were specialized in
phlebology but had no experience with the manage-
ment of DVTyet. It was sponsored by the Professional
Association of Phlebologists in Germany and logisti-
cally and financially supported by LEO Pharma
GmbH, Neu-Isenburg, Germany, and (to a smaller
extent) by Ganzoni and Cie SA, St Gallen, Switzerland.
Participating centres were invited to use the LWMH
tinzaparin (Innohepw, manufactured by LEO Pharma)
since this is the only LMWH registered in Germany for
once daily use covering all types of DVT and
pulmonary embolism. Graduated medical com-
pression stockings (Sigvarisw 503, ankle pressure 23–
32 mmHg, and 504, ankle pressure 34–46 mmHg,
manufactured by Ganzoni) were recommended since
data existed for their use in the management of acute
DVT.30,31 The companies had no influence on the
recruiting of centres, the monitoring of the program, or
the analysis and interpretation of data. Sixty-seven
physicians entered 827 patients in the registry termed
controlled outpatient treatment of DVT (COM I).
Inclusion in this series started in July 1999 and
concluded in December 2000. The results were com-
municated to the participating centres in September
2001.29
In July 2002 a questionnaire was sent to the
participating physicians. They were asked to report
on their approach toward and experience with further
patients with DVT covering the period from January
2002 to June 2002. This second survey was termed
COM II. Diagnosis and treatment were the same in
COM I and II and based on ACCP guidelines.26,29,32
This included anticoagulant treatment with a self-
injected LMWH for at least 5 days, phenprocoumon
started as early as possible and leg compression by
means of bandages and/or elastic compression stock-
ings combined with deliberate ambulation. Data were
collected retrospectively about each patient seen in theEur J Vasc Endovasc Surg Vol 30, September 2005study period. The inquiry covered the first 30 days
after diagnosis and focused on the patients’ charac-
teristics, the reasons for using outpatient treatment or
hospital admission, and the method of leg com-
pression. Assessment of clinical outcome and repeat
compression ultrasoundwas identical in COM I and II.
The criteria used to select outpatient treatment were
also the same. The participating centres proved their
competence in the outpatient management of DVT
during the COM I clinical series. Therefore, details of
outcome in COM II had to be reported only if an
unusual clinical course was encountered and no data
were collected on the quality of anticoagulant treat-
ment. Statistical analysis was performed using the
Mann–Whitney U-test and the Chi-squared tests.Results
In the prospective observational survey COM I (which
lasted 18 months) 67 centres registered a total of 827
patients. Twenty-six participants (39%) responded to
the second enquiry. These physicians† had enrolled
352 patients (43% of all patients) in COM I and
provided data on 540 patients treated in COM II
(which lasted 6 months). The case load in these
practices had increased by 450% from an average of
0.77 DVT/month to 3.46 DVT/month.
The demographic and clinical data of the patients in
COM I and II showed no difference. Of the 540 patients
included in COM II 211 had crural, 155 popliteal, 137
femoral, and 37 pelvic DVT. OT was chosen for 496
patients. The percentage of OT increased from 76 to
92%. The increase was the higher the more proximal
the DVTwas localised (Fig. 1).
The criteria for using OT were established before
COM I commenced and were the same in COM I and
II. They were summarised under two titles, either
medical or personal. Medical reasons to exclude the
use of OT included a decision to use thrombolysis or
thrombectomy for severe ischaemia, severe leg symp-
toms, pulmonary embolism, or poor general health.
Personal reasons included lack of time to provide
sufficient patient information and work-up, inability
of the patient to comply with the requirements of self-
treatment, and unwillingness of patients to give
consent for this mode of treatment. The relative
proportion of these reasons changed significantly
from COM I to COM II: medical reasons not to utilise
outpatient treatment were advanced less frequently




Fig. 1.Outpatient treatment as a function of the extent of DVT. The proportion of OT is reflected by the height of the columns.
The inserted number refers to the actual number of patients. In total, OTwas performed in 631 of 827 patients in COM I (76%)
and in 496 of 540 in COM II (92%). With experience, a greater proportion of proximal DVTwere treated on an outpatient basis.
Implementation of Outpatient Treatment of DVT 321same (Fig. 2). Obviously, experience led to a reconsi-
deration of the dangers of DVT.
Anticoagulant treatment with LMWH did not show
a difference between COM I and COM II. Tinzaparin
(175 U/kg b.w. once daily) was used in 23 of 26
practices. The start of oral anticoagulation with
phenprocoumon was on day 1 in 90 and 96% in
COM I and II, respectively. No data were collected on
the quality of anticoagulant control in COM II.
The mode of initial treatment with leg compression
showed a significant change of preference in the 26
centres participating in both inquiries. Bandages were
used by 20 centres in COM I but by only eight in COM 
  
  
Fig. 2. Reasons why outpatient treatment was not used. The
columns. The inserted numbers refer to the actual number o
decrease of medical reasons is statistically significant (p!.01).II. Correspondingly, medical compression stockings
were used by six centres in COM I but favoured by 18
in COM II (Fig. 3). Sigvaris 503/504 medical com-
pression stockings were used in 21 of 26 centres.
Compliance with treatment was reported to be
100%. By the end of the 1 month follow-up period
there was no clinical suspicion of pulmonary embo-
lism in any patient and no secondary hospitalisation
was necessary. Only one adverse event was documen-
ted (0.2%). A patient experienced asymptomatic
progression of DVT from popliteal to femoral. There
was no clear reason for this progression and the final
outcome was satisfactory resolution of the thrombus. 
 
proportion of statements is reflected by the height of the
f patients. Initial hesitation vanished with experience: the
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Fig. 3. Compression therapy. The method of initial leg compression changed from bandaging to medical compression
stockings (MCS) in 20 of 26 centres. The shift of preference is statistically significant (p!.05).
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In view of the uniformly positive results of random-
ised trials and management studies few would
challenge the evidence that patients with acute DVT
can be effectively and safely treated on an outpatient
basis. The achievable cost savings are enormous and
practicability has never been a true issue. Patient
satisfaction was high and quality of life restored
quickly in all studies that addressed these questions.
This and a previous report addmore than 1200 cases of
successful OT administered by physicians in private
practice.
Nevertheless, medical enthusiasm to adopt this
new strategy seems low. Claims for careful selection of
patients were made and warning criteria established
but not assessed in clinical studies.26 Clearly, the
number of prerequisites deemed necessary for a safe
outpatient treatment determines the proportion of
eligible patients. Thus, the process of patient selection
implies a political dimension. As shown by surveys in
Sweden and Germany, almost 20% of patients eligible
for OT were admitted to the ward because time and
resources thought to be essential for adequate work-
up and patient information were not available.12,25
Nationwide surveys in Spain and the USA showed
that the vast majority of patients are still admitted.27,28
It is highly unlikely that the large proportion of
hospital admissions would solely be due to the clinical
condition of the patients.
We learned from our long personal experience that
there is no reason to put the hurdles for outpatient
treatment too high. We intended to share ourEur J Vasc Endovasc Surg Vol 30, September 2005experience and straightforward approach with other
physicians in practice and to bypass the traditional
ways educational information is distributed and
implemented in order to bring training in new
treatment methods to physicians in our country.33
Members of the Professional Association of Phlebolo-
gists were provided with specific knowledge and
material to inform their referring physicians. As a
result, the case load increased substantially in dedi-
cated practices. Ambulatory treatment was expanded
to the extent that 97% of distal and 88.5% of proximal
DVT are now managed on an outpatient basis.
Another change of paradigm was noticed: com-
pression therapy with bandages was largely replaced
by the use of compression stockings which greatly
facilitate the application of compression.
The implementation of outpatient treatment was
paralleled by two clinical surveys which documented
not only the effectiveness, safety and practicability of
the procedures but in as much the sense of responsi-
bility of the participating physicians and their pro-
fessional organisation. The private enterprise allowed
rapid implementation of a new therapeutic approach,
which benefited the physicians in private practice.
There was also an advantage to the patients who
avoided hospital treatment and our healthcare system
which was saved the costs of inpatient treatment.
This report clearly has some limitations. Firstly, the
survey is not representative for the global situation in
Germany. Nationwide data, which would document a
shift from in-hospital to outpatient treatment, are not
available. Secondly, it suffers selection bias as no
information was available from practices that
Implementation of Outpatient Treatment of DVT 323participated in COM I but did not respond to the COM
II survey. We know that some phlebologists did not
want to or could not manage to establish themselves as
accepted specialists for the treatment of acute DVT.We
have received no report of any adverse experience
from physicians involved in these clinical series.
Thirdly, patients referred to private practices may
more likely be suitable for outpatient treatment as they
have less dramatic symptoms than those seen in
hospitals. Patient selection may also explain the
excellent outcome in which there was no instance of
clinically apparent pulmonary embolism or need for
hospitalisation. Whilst less severely affected patients
may have been treated by the medical practitioners
participating in this study, the results demonstrated
that this is a safe and effective method of management
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